SIRT5 antibodies are essential tools for studying the function and expression of Sirtuin 5 (SIRT5), a member of the sirtuin family of NAD⁺-dependent deacylases. SIRT5 is primarily localized in mitochondria and regulates post-translational modifications by removing succinyl, malonyl, and glutaryl groups from lysine residues on target proteins. It plays a critical role in metabolic pathways, including ketogenesis, fatty acid oxidation, and the urea cycle, impacting cellular energy homeostasis, stress responses, and apoptosis.
SIRT5 antibodies are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to detect SIRT5 expression levels, subcellular localization, and interaction partners. Their specificity is crucial, as commercial antibodies vary in performance across applications, requiring validation via knockout cell lines or tissues. Research involving SIRT5 antibodies has linked the protein to diseases such as cancer (where it may act as an oncogene or tumor suppressor), metabolic disorders, and neurodegenerative conditions. For instance, SIRT5 overexpression in certain cancers correlates with altered mitochondrial metabolism, while its deficiency has been implicated in cardiac and hepatic dysfunction.
These antibodies also aid in exploring SIRT5's therapeutic potential, as modulating its activity could influence age-related diseases or metabolic syndromes. However, challenges remain in standardizing antibody specificity and interpreting context-dependent roles of SIRT5 across tissues. Overall, SIRT5 antibodies are pivotal for unraveling the protein’s diverse biological functions and its implications in health and disease.